

HPV PREVENTION POLICY ATLAS

Joint project by EPF and ECO

September 2023

congress.esgo.org

Declaration of interests

MSD supported independent research conducted by EPF with a group of Experts.



About EPF





Bringing together Parliamentarians committed to protecting the sexual and reproductive health and rights of the world's most vulnerable.

EPF is a network of members of parliaments from across Europe who are committed to protecting the sexual and reproductive health of the world's most vulnerable people, both at home and overseas.



EPF Membership And Leadership



30 All Party Parliamentary Groups throughout Europe



Executive Committee

- Hon. Petra Bayr, MP (Austria), EPF President
- Hon. Bojan Glavasevic, MP (Croatia), Vice President
- Hon. Lina Lopes, MP (Portugal), Treasurer
- Hon. Morgana Daniele, MP (Lithuania)
- Sen Alice Mary Higgins (Ireland)
- Hon. Saara Hyrkko, MP (Finland)
- Hon. Goedele Liekens, MP (Belgium)
- Hon. Predrag Fred Matic (MEP)
- Hon. Lia Quartapelle, MP (Italy)
- Hon. Joanna Scheuring Wielgus, MP (Poland)



The Role Of Parliamentarians



Parliamentarians are uniquely positioned to influence the shape & content of their countries' public health agendas:

- Make the voice of affected citizens heard
- Lead the development of legislation & policies
- Monitor implementation
- Define the fiscal and budgetary regimes



Health Statistics



Each year in the WHO European Region

more than 66.000 women

are newly diagnosed with cervical cancer and

more than 30,000 women die

when we have the technical, medical and policy tools to eliminate cervical cancer.



What Is The Policy Atlas? (1)



- The HPV Prevention Policy Atlas is a comparative map that scores 47 countries across geographical Europe on prevention policies of cervical cancer.
- The Atlas focuses on:
- 1. Primary prevention of HPV related cancers through HPV vaccination;
- 2. Secondary prevention of HPV related cancer through screening programs;
- 3. Online information on HPV, cervical cancer and accessing vaccination.



What Is The Policy Atlas? (2)



- The Atlas does **not reflect the prevalence rate** of HPV related cancers such as cervical cancer in the countries.
- With 10 criteria and 19 sub-criteria established by a respected multi-stakeholder group of experts in cervical cancer and oncology, it ultimately aims to provide a living document which introduces a common baseline on prevention policies for HPV related cancer in Europe.
- 2023 Atlas adds 7 new criteria to the Atlas and includes scoring the VCR rates for boys and girls.




The Atlas Experts Group



- Dr. Margaret Stanley, Emeritus Professor of Epithelial Biology, University of Cambridge
- Dr. Murat Gultekin, Hacettepe University, Head of ESGO Prevention Committee and ENGAGe, Ankara, Türkiye
- Cătălin Teniță, Member of the Romanian Parliament (Chamber of Deputies)
- Professor Daniel Kelly, Co-Chair of the European Cancer Organisation's HPV Action Network
- Peter Baker, HPV Action Network Consultant, European Cancer Organisation
- Menia Koukougianni, Co-founder of NGO KARKINAKI, Awareness for Childhood and Adolescent Cancer, Greece
- Federica Marra, Communications Coordinator Think Young







24th European Congress on Gynaecological Oncology Sep 28 - Oct 1, 2023 | Istanbul, Türkiye



- The division between the West and East of Europe regarding HPV prevention policies is evident, with the West generally displaying more comprehensive and effective policies compared to the East.
- Good trends for Eastern European countries: policies have improved such as in North Macedonia, Moldova, Georgia, Slovakia, Poland.





- The division between the West and East of Europe regarding HPV prevention policies is evident, with the West generally displaying more comprehensive and effective policies compared to the East.
- Good trends for Eastern European countries: policies have improved such as in North Macedonia, Moldova, Georgia, Slovakia, Poland.







Excellent (>95%)	Very good (85-95%)	Medium (75-84%)	Poor (65-74%)	Very poor (50-64%)	Exceptionally Poor (<50)
5 champion countries	12 countries	7 countries	9 countries	7 countries	7 countries
Denmark 97,4 Sweden 97,4 Finland 96,1 UK 95,8 Ireland 95,2	Netherlands 94,2 Iceland 93,9 Germany 93,4 Norway 93,1 Malta 92,9 Switzerland 92,3 Estonia 91,7 Belgium 90,5 Latvia 88,8 France 86,6 Czech Republic 86,5 Italy 85,2	Poland 84,4 Hungary 84,3 Croatia 84,0 Portugal, 83,7 Austria 83,6 North Macedonia 80,7 Slovenia 80,7	Spain 78,1 Lithuania 73,9 Serbia 72,1 Andorra 70,5 Cyprus 70,1 Slovakia 66,4 Romania 65,7 Greece 65,5 Georgia 65	Armenia 64,4 Monaco, 63,5 Luxembourg 61,8 Moldova 61,7 Bulgaria 60,9 Montenegro 60,5 San Marino 54,1	Albania 39,5 Russia 37,4 Ukraine 33,8 Türkiye 31,6 Belarus 30,0 Bosnia- Herzegovina 21,5 Azerbaijan 6,4



Key Findings Primary Prevention

Excellent (>95%)	Very good (85-95%)	Medium (75-84%)	Poor (65-74%)	Very poor (50-64%)	Exceptionally Poor (<50)
 ✓ National policies on HPV vaccination that are funded ✓ National routine programme on vaccination, free ✓ Gender Neutral Vaccination ✓ Hight VCR for both girls and boys 	 ✓ National policies on HPV vaccination that are funded ✓ National routine programme on vaccination, free ✓ Gender Neutral Vaccination (exception Iceland and Estonia) ✓ Hight VCR for girls, low VCR for boys or N/A 	✓ National policies on HPV vaccination that are funded ✓ National routine programme on vaccination, free ✓ Gender Neutral Vaccination (exception North Macedonia) ✓ Average VCR for girls, low VCR for boys or N/A	✓ National policies on HPV vaccination that are funded ✓ National routine programme on vaccination, free or mostly reimbursed ✓ Mostly Gender Neutral Vaccination ✓ Average VCR for girls, low VCR for boys or N/A	✓ National policies on HPV vaccination that are funded ✓ National routine programme on vaccination, free or out of pocket ✓ Only girls vaccination (exception Monaco and Luxembourg) ✓ Low VCR for girls, low VCR for boys or N/A	✓ Recommen-dation only in some countries (no funding) ✓ No vaccination available (with the exception of Albania)



Key Findings Secondary Prevention

Excellent (>95%)	Very good (85-95%)	Medium (75-84%)	Poor (65-74%)	Very poor (50-64%)	Exceptionally Poor (<50)
 ✓ Mature organized screening program ✓ Free ✓ Availability of self-sampling ✓ Both PAP and HPV test available 	✓ Mature organized screening program ✓ Free (except for Belgium and Norway) ✓ Generally, no availability of self-sampling (Except for Netherlands, Germany and France)	 ✓ Opportunistic or Nascent organised screening program, free and co-payment ✓ No availability of self- sampling (Except for Portugal) 	 ✓ Opportunistic or Nascent organised screening program, free and co-payment ✓ No availability of self-sampling 	 ✓ Opportunistic screening program, co-payment or none available ✓ No availability of self-sampling 	✓ Opportunistic Screening ✓ No availability of self-sampling (Except for Albania)




Key Findings Online Information

Excellent (>95%)	Very good (85-95%)	Medium (75-84%)	Poor (65-74%)	Very poor (50-64%)	Exceptionally Poor (<50)
✓ Excellent information on HPV, cervical cancer and accessing vaccination ✓ Website provided by the government	✓ Good or excellent information on HPV, cervical cancer and accessing vaccination ✓ Website provided by the government or CSO	✓ Good or unsatisfactory quality of information on HPV, cervical cancer and accessing vaccination ✓ Website provided by the government or CSO	✓ Good or unsatisfactory quality of information on HPV, cervical cancer and accessing vaccination ✓ Website provided by non state actor, blogs, magazines, clinics	✓ Good or unsatisfactory quality of information on HPV, cervical cancer and accessing vaccination ✓ Website provided by non state actor, blogs, magazines, clnics	✓ Unsatisfactory quality of information on HPV, cervical cancer and accessing vaccination ✓ Website provided by non state actor, blogs, magazines, clinics

Denmark, Sweden and Finland are the policy champions





Primary prevention:

- Recommendation and funding on HPV Vaccination
- Free gender-neutral vaccination
- ✓ HPV vaccine registry
- ✓ Hight VCR for both girls and boys

Secondary prevention:

- Free population-based screening programme
- Availability of self-sampling
- ✓ PAP and HPV test provided

Online information:

Governmental websites with excellent information on HPV, screening and accessing the vaccine.



General Trends (2)

Azerbaijan and Bosnia-Herzegovina are the worst-performing countries





Bosnia-Herzegovina **26,3%**



Azerbaijan **9,3%**

Primary prevention:

- No recommendation no funding
- No access to vaccine

Secondary prevention:

- No screening / Opportunistic screening
- No self sampling

Online information:

Absence of reliable online information on the issue



Progress Since 2020

From 48 Countries Analysed



39 countries offer a national routine programme on vaccination: ↑ 4 countries

30 countries offer gender-neutral vaccination: ↑ **13 countries**

All countries except Azerbaijan offer screening programmes

24 countries offer mature population-based screening programmes:

↑ 6 countries

24 countries offer both PAP and HPV test or HPV alone: new criteria

23 countries have an HPV vaccine registry: new criteria

25 countries offer easy-to-find governmental websites with good or excellent information: ↑ 3 countries







EU – European Beating Cancer Plan (03.02.2021)

Vaccinate 90% of girls (2030) 90%
population
to have
access to
screening
(2025)

90% to have access to recognised National Comprehensive Cancer Centres (2030)

WHO: Global strategy to accelerate the elimination of cervical cancer as a public health problem (2020)

90% of girls vaccinated by age 15 years (2030) 70% of women are screened (35+45 years of age)

90% of women receive treatment

Key Conclusions



Cervical cancer is preventable

No woman should die
when we have the technical, medical
& policy tools to eliminate
HPV-related cervical cancer

Key Conclusions



There is a high inequality in access to vaccines and screening across Europe with worse indicators for Southern and Eastern Europe

Nevertheless, overwhelming majority of countries need to do more to put an end to preventable deaths

Key Conclusions



More reliable data is needed including vaccine and screening coverage

9 Key recommendations



States should:

- 1. Include HPV vaccination into routine state vaccination schedules
- 2. Establish **gender neutral vaccination** by including **boys** into HPV vaccination coverage (which also serves protection of the girls)
- 3. Offer the HPV vaccine free of charge
- 4. Provide mature **population-based screening** programmes which are the **only way** to reach the entire population and achieve results in saving women's lives
- 5. Ensure that screening is offered free of charge
- 6. Increase considerably the VCR and screening levels and make them publicly available
- 7. Offer screening by HPV testing and self-sampling options
- 8. Provide their citizens with reliable evidence-based information about HPV screening and vaccine and where to reach them
- 9. Ensure better data collection for HPV screening and coverage rate



24th European Congress on Gynaecological Oncology

Sep 28 - Oct 1, 2023 | Istanbul, Türkiye

Thank you!



- Expert Group
- European Public Health Authorities and Civil society for responding to our questionnaires
- MSD for supporting the independent research



congress.esgo.org